Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354042|
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : May 18, 2009
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: GW597901X||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects|
|Study Start Date :||August 2004|
- Safety Tolerability including blood test results, effects on the heart, pulse rate and blood pressure, and any side effects.
- Effects on the lungs at 12 and 24 hours Effects on the heart, blood pressure and heart rate at 8 hours Effects on blood tests over 4 hours and 8 hours Reduction of rescue medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354042
|Study Director:||GSK Clinical Trials, MD, MSc, FPPM||GlaxoSmithKline|